RecruitingRecruiting
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970 · AstraZeneca
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
ROSY-S: Rollover Study for Participants Who Have Completed a Previous Study With Anifrolumab (Saphnelo) and Are Assessed by the Investigator to Clinically Benefit From Continued Treatment
About this study
The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment at the end of a parent clinical study, as assessed by the Investigator, while monitoring safety and tolerability.
Study details include:
* Participants can transition in ROSY-S once they complete their participation in the parent study and should have received at least one dose of anifrolumab in the parent study. Participants with a treatment gap from parent studies and/or who are on compassionate use are eligible to rollover to ROSY-S study.
* The earliest that the Enrolment Visit may occur is at the time of the last visit of the parent study (ie, completion of the parent study's final safety follow-up visit). All required assessments from the safety follow-up visit of the parent study must be completed before the Enrolment Visit of ROSY-S study.
* The participants will continue to receive anifrolumab the same way they received it in the parent trial
* A participant is considered to have completed the study when they meet one of the discontinuation criteria.
* Safety will be monitored throughout the study. Both serious and nonserious AEs will be collected up to 12 weeks after the last dose of anifrolumab and will be reported as part of the primary safety endpoint.
Eligibility criteria
Inclusion Criteria:
* Participants are eligible to be included in the study only if all of the following criteria apply:
1 Participants must have completed the entirety of the parent study and should have received at least one dose of anifrolumab in the parent study.
* In the opinion of the Investigator, the potential benefit to the participant of continuing anifrolumab at the end of the parent study outweighs the risk.
* Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Participants should continue following the contraception requirements as per Appendix B from study enrolment up to 16 weeks after the last dose of study treatment.
* Capable of giving signed informed consent described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
* Capable of adhering to the treatment plan related to this ROSY-S study.
Exclusion Criteria:
* Participant develops hypersensitivity to any of the components of anifrolumab.
* Female participant who is breastfeeding, pregnant, or intends to become pregnant during participation in this study.
* Currently participating in any investigational study or participated in an investigational study within 30 days prior to enrolment or within 5 half-lives of the investigational medicinal product (other than the parent study for anifrolumab) whichever is longer.
* Ongoing, unresolved AE requiring interruption of treatment at the end of the prior parent study (ie, when the parent study is either completed or closed) that in the Investigator's opinion would prevent restarting anifrolumab.
* Currently receiving or have received prohibited medication(s) as specified in parent protocols prior to signing ICF.
* Participants who are planning to use live/live-attenuated vaccines.
* Participants who are planning to use any other therapies, including B-cell therapies, that in the opinion of the Investigator could jeopardize or would compromise the participant's ability to participate in the program as determined by the Investigator.
* Participants with any medical condition (such as cancer or viral infections \[hepatitis\]) or psychiatric condition that, in the opinion of the Investigator, could jeopardise or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments.
* Participants who discontinued the parent study prior to completion of all study visits.
* Local access to approved and commercially available (reimbursed) drug for the defined indication as permitted by local/country regulation.
Study design
Enrollment target: 1072 participants
Allocation: non_randomized
Masking: none
Age groups: child, adult, older_adult
Timeline
Starts: 2026-08-31
Estimated completion: 2032-12-30
Last updated: 2026-11-10
Interventions
Combination Product: AnifrolumabCombination Product: AnifrolumabDrug: Anifrolumab
Primary outcomes
- • SAEs and Non-Serious AEs (From first dose administered and until 12 weeks after the last dose of Anifrolumab)
Sponsor
AstraZeneca · industry
Contacts & investigators
ContactAstraZeneca Clinical Study Information Center · contact · information.center@astrazeneca.com · +1877-240-9479
All locations (166)
Research SiteNot Yet Recruiting
Phoenix, Arizona, United States
Research SiteNot Yet Recruiting
Irvine, California, United States
Research SiteRecruiting
Los Angeles, California, United States
Research SiteNot Yet Recruiting
San Francisco, California, United States
Research SiteRecruiting
Boca Raton, Florida, United States
Research SiteRecruiting
Fort Lauderdale, Florida, United States
Research SiteNot Yet Recruiting
Chicago, Illinois, United States
Research SiteNot Yet Recruiting
Indianapolis, Indiana, United States
Research SiteNot Yet Recruiting
Baltimore, Maryland, United States
Research SiteNot Yet Recruiting
Boston, Massachusetts, United States
Research SiteNot Yet Recruiting
Ann Arbor, Michigan, United States
Research SiteNot Yet Recruiting
Rochester, Minnesota, United States
Research SiteNot Yet Recruiting
Omaha, Nebraska, United States
Research SiteNot Yet Recruiting
New York, New York, United States
Research SiteRecruiting
Charlotte, North Carolina, United States
Research SiteNot Yet Recruiting
Cleveland, Ohio, United States
Research SiteNot Yet Recruiting
Columbus, Ohio, United States
Research SiteNot Yet Recruiting
Portland, Oregon, United States
Research SiteNot Yet Recruiting
Charleston, South Carolina, United States
Research SiteNot Yet Recruiting
Dallas, Texas, United States
Research SiteNot Yet Recruiting
Roanoke, Virginia, United States
Research SiteNot Yet Recruiting
Quilmes, Argentina
Research SiteNot Yet Recruiting
San Miguel, Argentina
Research SiteNot Yet Recruiting
Melbourne, Australia
Research SiteNot Yet Recruiting
Mitcham, Australia
Research SiteNot Yet Recruiting
Westmead, Australia
Research SiteNot Yet Recruiting
Graz, Austria
Research SiteNot Yet Recruiting
Graz, Austria
Research SiteNot Yet Recruiting
Linz, Austria
Research SiteNot Yet Recruiting
Vienna, Austria
Research SiteNot Yet Recruiting
Ghent, Belgium
Research SiteNot Yet Recruiting
Leuven, Belgium
Research SiteNot Yet Recruiting
Belo Horizonte, Brazil
Research SiteNot Yet Recruiting
Porto Alegre, Brazil
Research SiteNot Yet Recruiting
Rio de Janeiro, Brazil
Research SiteNot Yet Recruiting
Salvador, Brazil
Research SiteNot Yet Recruiting
São Paulo, Brazil
Research SiteNot Yet Recruiting
Haskovo, Bulgaria
Research SiteNot Yet Recruiting
Plovdiv, Bulgaria
Research SiteNot Yet Recruiting
Sofia, Bulgaria
Research SiteNot Yet Recruiting
Sofia, Bulgaria
Research SiteNot Yet Recruiting
Toronto, Ontario, Canada
Research SiteNot Yet Recruiting
Québec, Canada
Research SiteNot Yet Recruiting
Santiago, Chile
Research SiteNot Yet Recruiting
Beijing, China
Research SiteNot Yet Recruiting
Chongqing, China
Research SiteNot Yet Recruiting
Guangzhou, China
Research SiteNot Yet Recruiting
Jinan, China
Research SiteNot Yet Recruiting
Lanzhou, China
Research SiteNot Yet Recruiting
Shanghai, China
Research SiteNot Yet Recruiting
Shenzhen, China
Research SiteNot Yet Recruiting
Shenzhen, China
Research SiteNot Yet Recruiting
Bogotá, Colombia
Research SiteNot Yet Recruiting
Prague, Czechia
Research SiteNot Yet Recruiting
Bordeaux, France
Research SiteNot Yet Recruiting
Nantes, France
Research SiteNot Yet Recruiting
Paris, France
Research SiteNot Yet Recruiting
Paris, France
Research SiteNot Yet Recruiting
Paris, France
Research SiteNot Yet Recruiting
Poitiers, France
Research SiteNot Yet Recruiting
Rennes, France
Research SiteNot Yet Recruiting
Strasbourg, France
Research SiteNot Yet Recruiting
Toulouse, France
Research SiteNot Yet Recruiting
Toulouse, France
Research SiteNot Yet Recruiting
Berlin, Germany
Research SiteNot Yet Recruiting
Dresden, Germany
Research SiteNot Yet Recruiting
Essen, Germany
Research SiteNot Yet Recruiting
Freiburg im Breisgau, Germany
Research SiteNot Yet Recruiting
Freiburg im Breisgau, Germany
Research SiteNot Yet Recruiting
Hanover, Germany
Research SiteNot Yet Recruiting
Kiel, Germany
Research SiteNot Yet Recruiting
Mainz, Germany
Research SiteNot Yet Recruiting
Marburg, Germany
Research SiteNot Yet Recruiting
Münster, Germany
Research SiteNot Yet Recruiting
Regensburg, Germany
Research SiteNot Yet Recruiting
Tübingen, Germany
Research SiteNot Yet Recruiting
Wuppertal, Germany
Research SiteNot Yet Recruiting
Chaïdári, Greece
Research SiteNot Yet Recruiting
Hyderabad, India
Research SiteNot Yet Recruiting
Kolkata, India
Research SiteNot Yet Recruiting
New Delhi, India
Research SiteNot Yet Recruiting
Pune, India
Research SiteNot Yet Recruiting
Haifa, Israel
Research SiteNot Yet Recruiting
Kfar Saba, Israel
Research SiteNot Yet Recruiting
Brescia, Italy
Research SiteNot Yet Recruiting
Catania, Italy
Research SiteNot Yet Recruiting
Cona, Italy
Research SiteNot Yet Recruiting
Florence, Italy
Research SiteNot Yet Recruiting
Milan, Italy
Research SiteNot Yet Recruiting
Milan, Italy
Research SiteNot Yet Recruiting
Naples, Italy
Research SiteNot Yet Recruiting
Pavia, Italy
Research SiteNot Yet Recruiting
Roma, Italy
Research SiteNot Yet Recruiting
Roma, Italy
Research SiteNot Yet Recruiting
Fukuoka, Japan
Research SiteNot Yet Recruiting
Kanazawa, Japan
Research SiteNot Yet Recruiting
Maebashi, Japan
Research SiteNot Yet Recruiting
Nagoya, Japan
Research SiteNot Yet Recruiting
Sapporo, Japan
Research SiteNot Yet Recruiting
Yokohama, Japan
Research SiteNot Yet Recruiting
Guadalajara, Mexico
Research SiteNot Yet Recruiting
Guadalajara, Mexico
Research SiteNot Yet Recruiting
México, Mexico
Research SiteNot Yet Recruiting
San Luis Potosí City, Mexico
Research SiteNot Yet Recruiting
Veracruz, Mexico
Research SiteNot Yet Recruiting
Rotterdam, Netherlands
Research SiteNot Yet Recruiting
Iloilo City, Philippines
Research SiteNot Yet Recruiting
Lipa City, Philippines
Research SiteNot Yet Recruiting
Manila, Philippines
Research SiteNot Yet Recruiting
Bydgoszcz, Poland
Research SiteNot Yet Recruiting
Katowice, Poland
Research SiteNot Yet Recruiting
Kielce, Poland
Research SiteNot Yet Recruiting
Krakow, Poland
Research SiteNot Yet Recruiting
Krakow, Poland
Research SiteNot Yet Recruiting
Lodz, Poland
Research SiteNot Yet Recruiting
Ossy, Poland
Research SiteNot Yet Recruiting
Warsaw, Poland
Research SiteNot Yet Recruiting
Braga, Portugal
Research SiteNot Yet Recruiting
Lisbon, Portugal
Research SiteNot Yet Recruiting
Porto, Portugal
Research SiteNot Yet Recruiting
Bucharest, Romania
Research SiteNot Yet Recruiting
Cluj-Napoca, Romania
Research SiteNot Yet Recruiting
Iași, Romania
Research SiteNot Yet Recruiting
Belgrade, Serbia
Research SiteNot Yet Recruiting
Kragujevac, Serbia
Research SiteNot Yet Recruiting
Košice, Slovakia
Research SiteNot Yet Recruiting
Piešťany, Slovakia
Research SiteNot Yet Recruiting
Johannesburg, South Africa
Research SiteNot Yet Recruiting
Seoul, South Korea
Research SiteNot Yet Recruiting
Seoul, South Korea
Research SiteNot Yet Recruiting
Seoul, South Korea
Research SiteNot Yet Recruiting
Seoul, South Korea
Research SiteNot Yet Recruiting
Seoul, South Korea
Research SiteNot Yet Recruiting
A Coruña, Spain
Research SiteNot Yet Recruiting
Barcelona, Spain
Research SiteNot Yet Recruiting
Barcelona, Spain
Research SiteNot Yet Recruiting
Barcelona, Spain
Research SiteNot Yet Recruiting
Castellon, Spain
Research SiteNot Yet Recruiting
Granada, Spain
Research SiteNot Yet Recruiting
Las Palmas de Gran Canaria, Spain
Research SiteNot Yet Recruiting
Madrid, Spain
Research SiteNot Yet Recruiting
Madrid, Spain
Research SiteNot Yet Recruiting
Madrid, Spain
Research SiteNot Yet Recruiting
Valencia, Spain
Research SiteNot Yet Recruiting
Valencia, Spain
Research SiteNot Yet Recruiting
Valladolid, Spain
Research SiteNot Yet Recruiting
Vigo, Spain
Research SiteNot Yet Recruiting
Kaohsiung City, Taiwan
Research SiteNot Yet Recruiting
Kaohsiung City, Taiwan
Research SiteNot Yet Recruiting
Taichung, Taiwan
Research SiteNot Yet Recruiting
Taichung, Taiwan
Research SiteNot Yet Recruiting
Taipei, Taiwan
Research SiteNot Yet Recruiting
Bangkok, Thailand
Research SiteNot Yet Recruiting
Bangkok, Thailand
Research SiteNot Yet Recruiting
Hat Yai, Thailand
Research SiteNot Yet Recruiting
Khon Kaen, Thailand
Research SiteNot Yet Recruiting
Klong Luang, Thailand
Research SiteNot Yet Recruiting
Fatih-Istanbul, Turkey (Türkiye)
Research SiteNot Yet Recruiting
Ümraniye, Turkey (Türkiye)
Research SiteNot Yet Recruiting
Cambridge, United Kingdom
Research SiteNot Yet Recruiting
Leeds, United Kingdom
Research SiteNot Yet Recruiting
London, United Kingdom
Research SiteNot Yet Recruiting
London, United Kingdom
Research SiteNot Yet Recruiting
Newcastle upon Tyne, United Kingdom
Research SiteNot Yet Recruiting
Sheffield, United Kingdom
Research SiteNot Yet Recruiting
Hà Nội, Vietnam